CAVERJECT contains alprostadil as the naturally occurring form of prostaglandin E1(PGE1).
CAVERJECT (CAVERJECT IMPULSE, CAVERJECT Sterile Powder, and CAVERJECT Injection) is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
Intracavernosal CAVERJECT is also indicated as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
Media Articles Related to Caverject (Alprostadil)
Vitaros® (alprostadil), the first cream to treat men with erectile dysfunction, is now available for prescription in the UK
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2014.06.17]
The first topical cream approved for the treatment of erectile dysfunction (ED) in men over the age of 18 years, Vitaros® (topical alprostadil cream), is now available for prescription in the...
Published Studies Related to Caverject (Alprostadil)
Alprostadil infusion in patients with dry age related macular degeneration: a
randomized controlled clinical trial. 
alprostadil infusion in patients with dAMD... CONCLUSION: A numerical treatment effect in favor of alprostadil was visible,
[Clinical effects of alprostadil injection on acute kidney injury after cardiac surgical procedures]. [2010.08.24]
OBJECTIVE: To explore the clinical effects of alprostadil injection on acute kidney injury (AKI) after cardiac surgical procedures by a prospective randomized controlled trial... CONCLUSION: On the basis of routine therapy, alprostadil injection may promote the recovery of renal function in AKI-patients after cardiac surgical procedures.
Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. [2010.06]
PURPOSE: To our knowledge we report the first large, randomized, prospective penile rehabilitation clinical trial to compare the effectiveness of nightly intraurethral alprostadil vs sildenafil citrate after nerve sparing prostatectomy... CONCLUSIONS: This is the first study to directly compare the ability of alprostadil and a phosphodiesterase-5 inhibitor to enhance penile recovery subsequent to bilateral nerve sparing radical prostatectomy. The use of nightly subtherapeutic intraurethral alprostadil is well tolerated after radical prostatectomy. The benefit to return of erectile function of nightly sildenafil citrate and subtherapeutic intraurethral alprostadil appears to be comparable within the first year of surgery. Copyright 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. [2009.02]
INTRODUCTION: Alprostadil is approved for treatment of male erectile dysfunction (ED) by injection or urethral insertion. Topical delivery of alprostadil offers an improved alternative. AIM: To evaluate the long-term safety and efficacy of topical alprostadil cream... CONCLUSIONS: Topical alprostadil cream was considered effective and safe by most patients and their partners, with most AEs limited to the application site. Dose adjustment to 300 mcg alprostadil facilitated the greatest improvement in erectile function in the majority of patients. A separate report will integrate patient data from the open-label extension and prior double-blind studies.
[Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases] [2008.11.11]
OBJECTIVE: To investigate the therapeutic effects of alprostadil (Lipo-PGE1) and Ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass (CPB) in pediatric patients with congenital heart diseases... CONCLUSION: Decreasing the inflammatory response after CPB, alprostadil and ulinastatin used during CPB effectively reduce the pulmonary injury via inhibition of the neutrophil activation and cytokines release.
Clinical Trials Related to Caverject (Alprostadil)
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV [Recruiting]
The study is to confirmedly show a superior effect of Alprostadil compared to placebo on the
rate of complete healing of ischemic necroses and ulcerations.
Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF) [Not yet recruiting]
This is a randomized controlled trial (RCT) on the use of Inhaled prostaglandin E1 (IPGE1)
in Neonatal Hypoxemic Respiratory Failure (NHRF). Fifty patients recruited at 10 high
volume sites within the NICHD Neonatal Research Network will constitute a pilot sample to
evaluate the feasibility and safety of prolonged IPGE1 administration and determination of
optimal dose. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be
administered over a maximum duration of 72 hours and compared with placebo. Once
feasibility and safety of IPGE1 administered over 72 hours has been demonstrated in the
pilot trial, a full scale randomized controlled trial will be planned.
Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction [Not yet recruiting]
A Phase 4 clinical trial that is open, with no blinding of subjects or randomization of
treatment. Patients with erectile problems will be given the approved drug Vitaros to treat
their condition. They will be given forms and questionnaires to complete. The information
collected will be used to assess the effectiveness, safety and the satisfaction levels with
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure [Recruiting]
This pilot study is a randomized, placebo-controlled, clinical trial to test the safety of
using the intravenous form of Prostaglandin E1 (PGE1) in an inhaled form for treatment of
hypoxemic respiratory failure in term newborns. The study will enroll 50 infants diagnosed
with hypoxemic respiratory failure at nine NICHD Neonatal Research Network sites, and
randomly assign them to receive one dose over a 72-hour period of either high concentration
PGE1 (300 ng/kg/min), low concentration PGE1 (150 ng/kg/min), or placebo (normal saline, the
diluent for the drug). In addition to determining the safety, optimal dose, and duration of
the therapy, this pilot trial will evaluate the feasibility of conducting a larger,
multi-center randomized, blinded placebo-controlled trial.
Alprostadil Continuous Intravenous Infusion in Bridging Cardiac Transplant in Severe Heart Failure Patients [Not yet recruiting]
This is a multicenter, double blind, placebo-controlled, randomized, parallel group study
that compares Alprostadil given in a low, fixed-dose continuous infusion and placebo. The
difference between the two groups for the primary endpoints will be compared after 24 weeks
(Outpatient Double-Blind Treatment Phase). Thereafter, patients will continue on blinded
treatment and observation to all continued assessment of survival and cardiac-specific
mortality (Follow-Up Phase). It is planned that approximately 550 patients with advanced
heart failure be randomized (see Inclusion and Exclusion Criteria
Reports of Suspected Caverject (Alprostadil) Side Effects
Drug Ineffective (26),
Penis Disorder (7),
Erectile Dysfunction (6),
Penile Pain (5),
Expired Drug Administered (5),
Drug Effect Decreased (5),
Erection Increased (5),
Peyronie's Disease (4),
Poor Quality Drug Administered (4),
Prostatic Disorder (3), more >>
Page last updated: 2014-11-30